Evaluation of The effect of tocilizumab on patients with severe Covid 19

Phase 3

Recruiting

• Conditions: Covid_19.; Corona virus infection, unspecified; U07.1

• Registration Number: IRCT20210408050899N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Positive PCR test for COVID- 19
Oxygen saturation less than 90%
Hospitalized with pneumonia
High levels of interleukin 6
Not participating in another study

Exclusion Criteria

Pregnant or lactating women
Severe liver disease (liver enzymes more than 5 times normal)
Allergic reaction to the used drugs
Neutrophils less than 500
Platelets less than 50000
Intestinal diverticulosis or intestinal perforation
Positive viral markers or positive tuberculosis skin test

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality rate. Timepoint: End of study. Method of measurement: Patient file.

Secondary Outcome Measures

Name	Time	Method
Hospitalized in the intensive care unit. Timepoint: End of study. Method of measurement: Patient file.;Number of days hospitalized in the intensive care unit. Timepoint: End of study. Method of measurement: Patient file.;Interleukin 6. Timepoint: Before and after the intervention. Method of measurement: Measuring kit.